The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

Novo Nordisk and a popular virtual health company are making Wegovy more accessible to millions of more Americans. Hims & ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

The chart below compares the cost of an annualized semaglutide dosage from Hims, versus competitors: The pivot to liraglutide will allow Hims & Hers to prolong its operations in the weight-loss ...

If the drug shortage has been ... that these drugs can continue to be compounded if they add other vitamins or minerals to it, making it different enough and not available commercially. I’ve seen many ...

There have been reports of dosing errors associated with compounded semaglutide products, and some medical societies urge caution. Patients, however, have been attracted to affordability.

While there is not currently a shortage of Ozempic, previous difficulties in supplying this medication have led to some pharmacies offering compounded semaglutide. The Food and Drug Administration ...